Showing results (131-140 of 145) with videos related to

Sort By:
Pageof 15
The New England Journal of Medicine|January 23, 1997
Ventricular dysfunction and the risk of stroke after myocardial infarctionE Loh, M S Sutton, C C Wun, et al.
Heart (British Cardiac Society)|September 6, 2006
Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programmeN M Hawkins, D Wang, J J V McMurray, et al.
Journal of the American College of Cardiology|July 21, 1998
Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trialS J Lewis, F M Sacks, J S Mitchell, et al.
American Heart Journal|October 31, 2000
Valsartan in acute myocardial infarction trial (VALIANT): rationale and designM A Pfeffer, J McMurray, A Leizorovicz, et al.
The New England Journal of Medicine|April 18, 1996
Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular massK Lindpaintner, M Lee, M G Larson, et al.
Annals of Internal Medicine|December 5, 1998
Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trialS J Lewis, L A Moye, F M Sacks, et al.
Journal of the American College of Cardiology|February 6, 1999
Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent EventsM A Pfeffer, F M Sacks, L A Moyé, et al.
Circulation|January 20, 1999
Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care InvestigatorsJ F Plehn, B R Davis, F M Sacks, et al.
The New England Journal of Medicine|October 3, 1996
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigatorsF M Sacks, M A Pfeffer, L A Moye, et al.
Circulation|June 17, 1997
Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trialM A Pfeffer, S C Greaves, J M Arnold, et al.
Pageof 15